Development of CpG ODN Based Vaccine Adjuvant Formulations

Methods Mol Biol. 2016:1404:289-298. doi: 10.1007/978-1-4939-3389-1_20.

Abstract

Development of effective vaccine mediated immune responses relies on the use of vaccine adjuvants capable of enhancing and directing the adaptive immune response to the antigen. When used as vaccine adjuvants, type I interferon inducing agents can elicit potent effector/memory T cell responses and humoral immunity. Distinct sequences of single stranded synthetic oligodeoxynucleotides containing unmethylated cytosine-phosphate-guanine oligodeoxynucleotide motifs (CpG ODN) can generate type I interferon production via a TLR9-MyD88-IRF7-mediated signaling pathway. Here, we describe two different methods of preparing CpG ODN-based vaccine adjuvant formulations that can induce a robust IFNα response from human peripheral blood mononuclear cells.

Keywords: Cationic peptides; CpG ODN; Immune response; Liposomes; TLR9; Vaccine adjuvant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / chemistry*
  • Adjuvants, Immunologic / pharmacology*
  • Amino Acid Sequence
  • Base Sequence
  • CpG Islands*
  • Drug Compounding / methods*
  • Drug Stability
  • Electrophoresis, Agar Gel
  • Humans
  • Interferon-alpha / blood
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Liposomes / chemistry
  • Oligodeoxyribonucleotides / chemistry*
  • Oligodeoxyribonucleotides / immunology*
  • Peptides / chemistry

Substances

  • Adjuvants, Immunologic
  • Interferon-alpha
  • Liposomes
  • Oligodeoxyribonucleotides
  • Peptides